Eikonoklastes, Forge announce partnership to develop ALS gene therapy Posted on November 29, 2022 (November 29, 2022) […] Read More… from Eikonoklastes, Forge announce partnership to develop ALS gene therapy
Forge Biologics’ Gene Therapy Shows Positive Signals in Krabbe Disease Posted on October 11, 2022 (October 12, 2022) […] Read More… from Forge Biologics’ Gene Therapy Shows Positive Signals in Krabbe Disease
Columbus grows its gene therapy expertise Posted on May 12, 2022 (May 12, 2022) […] Read More… from Columbus grows its gene therapy expertise
Forge Biologics shares plans for growth at Meeting on the Med Posted on April 29, 2022 (May 2, 2022) […] Read More… from Forge Biologics shares plans for growth at Meeting on the Med
Forge Biologics closed an additional $80M financing to accelerate the company’s planned CDMO expansion Posted on January 13, 2022 (January 18, 2022) […] Read More… from Forge Biologics closed an additional $80M financing to accelerate the company’s planned CDMO expansion
Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord Posted on October 6, 2021 (October 15, 2021) […] Read More… from Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord
Solid Biosciences, Forge Biologics Enter Development and Manufacturing Pact Posted on October 5, 2021 (October 14, 2021) […] Read More… from Solid Biosciences, Forge Biologics Enter Development and Manufacturing Pact
EMA Orphan Drug Designation for Forge Biologics’ gene therapy for Krabbe disease Posted on September 23, 2021 (October 14, 2021) […] Read More… from EMA Orphan Drug Designation for Forge Biologics’ gene therapy for Krabbe disease
